These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

232 related items for PubMed ID: 9605129

  • 1. Perforin and IFN-gamma are involved in the antitumor effects of antibody-targeted superantigens.
    Rosendahl A, Kristensson K, Hansson J, Riesbeck K, Kalland T, Dohlsten M.
    J Immunol; 1998 Jun 01; 160(11):5309-13. PubMed ID: 9605129
    [Abstract] [Full Text] [Related]

  • 2. The distinct role of CD4+ and CD8+ T-cells during the anti-tumour effects of targeted superantigens.
    Litton MJ, Dohlsten M, Rosendahl A, Ohlsson L, Søgaard M, Andersson J, Andersson U.
    Br J Cancer; 1999 Sep 01; 81(2):359-66. PubMed ID: 10496366
    [Abstract] [Full Text] [Related]

  • 3. Antibody-targeted superantigen therapy induces tumor-infiltrating lymphocytes, excessive cytokine production, and apoptosis in human colon carcinoma.
    Litton MJ, Dohlsten M, Lando PA, Kalland T, Ohlsson L, Andersson J, Andersson U.
    Eur J Immunol; 1996 Jan 01; 26(1):1-9. PubMed ID: 8566049
    [Abstract] [Full Text] [Related]

  • 4. Combining tumor-targeted superantigens with interferon-alpha results in synergistic anti-tumor effects.
    Sundstedt A, Celander M, Hedlund G.
    Int Immunopharmacol; 2008 Mar 01; 8(3):442-52. PubMed ID: 18279798
    [Abstract] [Full Text] [Related]

  • 5. Immunopharmacology of the superantigen staphylococcal enterotoxin A in T-cell receptor V beta 3 transgenic mice.
    Dohlsten M, Björklund M, Sundstedt A, Hedlund G, Samson D, Kalland T.
    Immunology; 1993 Aug 01; 79(4):520-7. PubMed ID: 7691731
    [Abstract] [Full Text] [Related]

  • 6. Intratumoral IL-18 gene transfer improves therapeutic efficacy of antibody-targeted superantigen in established murine melanoma.
    Wang Q, Yu H, Ju DW, He L, Pan JP, Xia DJ, Zhang LH, Cao X.
    Gene Ther; 2001 Apr 01; 8(7):542-50. PubMed ID: 11319621
    [Abstract] [Full Text] [Related]

  • 7. Adenovirus-mediated intratumoral lymphotactin gene transfer potentiates the antibody-targeted superantigen therapy of cancer.
    Wang Q, Yu H, Zhang L, Ju D, Pan J, Xia D, Yao H, Zhang W, Wang J, Cao X.
    J Mol Med (Berl); 2002 Sep 01; 80(9):585-94. PubMed ID: 12226740
    [Abstract] [Full Text] [Related]

  • 8. Tumor therapy with an antibody-targeted superantigen generates a dichotomy between local and systemic immune responses.
    Litton MJ, Dohlsten M, Hansson J, Rosendahl A, Ohlsson L, Kalland T, Andersson J, Andersson U.
    Am J Pathol; 1997 May 01; 150(5):1607-18. PubMed ID: 9137087
    [Abstract] [Full Text] [Related]

  • 9. Differential requirement of perforin and IFN-gamma in CD8 T cell-mediated immune responses against B16.F10 melanoma cells expressing a viral antigen.
    Prévost-Blondel A, Neuenhahn M, Rawiel M, Pircher H.
    Eur J Immunol; 2000 Sep 01; 30(9):2507-15. PubMed ID: 11009083
    [Abstract] [Full Text] [Related]

  • 10. Involvement of tumor necrosis factor-related apoptosis-inducing ligand in NK cell-mediated and IFN-gamma-dependent suppression of subcutaneous tumor growth.
    Takeda K, Smyth MJ, Cretney E, Hayakawa Y, Yamaguchi N, Yagita H, Okumura K.
    Cell Immunol; 2001 Dec 15; 214(2):194-200. PubMed ID: 12088418
    [Abstract] [Full Text] [Related]

  • 11. Immunoregulatory role of IL-10 during superantigen-induced hyporesponsiveness in vivo.
    Sundstedt A, Höiden I, Rosendahl A, Kalland T, van Rooijen N, Dohlsten M.
    J Immunol; 1997 Jan 01; 158(1):180-6. PubMed ID: 8977189
    [Abstract] [Full Text] [Related]

  • 12. Differential antitumor effects of administration of recombinant IL-18 or recombinant IL-12 are mediated primarily by Fas-Fas ligand- and perforin-induced tumor apoptosis, respectively.
    Hashimoto W, Osaki T, Okamura H, Robbins PD, Kurimoto M, Nagata S, Lotze MT, Tahara H.
    J Immunol; 1999 Jul 15; 163(2):583-9. PubMed ID: 10395644
    [Abstract] [Full Text] [Related]

  • 13. Immune response during tumor therapy with antibody-superantigen fusion proteins.
    Rosendahl A, Hansson J, Sundstedt A, Kalland T, Dohlsten M.
    Int J Cancer; 1996 Sep 27; 68(1):109-13. PubMed ID: 8895549
    [Abstract] [Full Text] [Related]

  • 14. Regulation of superantigen-induced T cell activation in the absence and the presence of MHC class II.
    Lando PA, Olsson C, Kalland T, Newton D, Kotb M, Dohlsten M.
    J Immunol; 1996 Oct 01; 157(7):2857-63. PubMed ID: 8816390
    [Abstract] [Full Text] [Related]

  • 15. Monotherapeutically nonactive CTLA-4 blockade results in greatly enhanced antitumor effects when combined with tumor-targeted superantigens in a B16 melanoma model.
    Sundstedt A, Celander M, Eriksson H, Törngren M, Hedlund G.
    J Immunother; 2012 May 01; 35(4):344-53. PubMed ID: 22495392
    [Abstract] [Full Text] [Related]

  • 16. Superantigen-induced apoptotic death of tumor cells is mediated by cytotoxic lymphocytes, cytokines, and nitric oxide.
    Mondal TK, Bhatta D, Biswas S, Pal P.
    Biochem Biophys Res Commun; 2002 Feb 01; 290(4):1336-42. PubMed ID: 11812010
    [Abstract] [Full Text] [Related]

  • 17. Perforin, Fas ligand, and tumor necrosis factor are the major cytotoxic molecules used by lymphokine-activated killer cells.
    Lee RK, Spielman J, Zhao DY, Olsen KJ, Podack ER.
    J Immunol; 1996 Sep 01; 157(5):1919-25. PubMed ID: 8757310
    [Abstract] [Full Text] [Related]

  • 18. Critical contribution of IFN-gamma and NK cells, but not perforin-mediated cytotoxicity, to anti-metastatic effect of alpha-galactosylceramide.
    Hayakawa Y, Takeda K, Yagita H, Kakuta S, Iwakura Y, Van Kaer L, Saiki I, Okumura K.
    Eur J Immunol; 2001 Jun 01; 31(6):1720-7. PubMed ID: 11385616
    [Abstract] [Full Text] [Related]

  • 19. Tumor regression after adoptive transfer of effector T cells is independent of perforin or Fas ligand (APO-1L/CD95L).
    Winter H, Hu HM, Urba WJ, Fox BA.
    J Immunol; 1999 Oct 15; 163(8):4462-72. PubMed ID: 10510388
    [Abstract] [Full Text] [Related]

  • 20. Immunotherapy with tumor-targeted superantigens (TTS) in combination with docetaxel results in synergistic anti-tumor effects.
    Sundstedt A, Celander M, Ohman MW, Forsberg G, Hedlund G.
    Int Immunopharmacol; 2009 Aug 15; 9(9):1063-70. PubMed ID: 19410661
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.